Literature DB >> 22650354

Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine.

Newton Wahome1, Tanya Pfeiffer, Ina Ambiel, Yongkun Yang, Oliver T Keppler, Valerie Bosch, Peter Burkhard.   

Abstract

The self-assembling protein nanoparticle (SAPN) is an antigen-presenting system that has been shown to be suitable for use as a vaccine platform. The SAPN scaffold is based on the principles of icosahedral symmetry, beginning from a monomeric chain that self-assembles into an ordered oligomeric state. The monomeric chain contains two covalently linked α-helical coiled-coil domains, an N-terminal de novo-designed pentameric tryptophan zipper and a C-terminal de novo-designed trimeric leucine zipper, which assemble along the internal symmetry axes of an icosahedron. In this study, we incorporated the membrane proximal external region (MPER) of HIV-1 gp41 from HXB2 into the N-terminal pentamer, referred to as MPER-SAPN, attempting to reproduce the α-helical state of the 4E10 epitope while maintaining a structurally less-constrained 2F5 epitope. Sprague-Dawley rats were immunized with MPER-SAPNs, and their sera were analyzed for induced humoral anti-HIV-1 responses. We show that high membrane proximal external region-specific titers can be raised via the repetitive antigen display of MPER on the SAPN without the need for adjuvant. However, none of the sera displayed a detectable neutralizing activity against HIV-1. Thus, 4E10- and 2F5-like neutralizing antibodies could not be elicited by MPER conformationally restrained in the SAPN context.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22650354     DOI: 10.1111/j.1747-0285.2012.01423.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  39 in total

1.  Principles Governing the Self-Assembly of Coiled-Coil Protein Nanoparticles.

Authors:  Giuliana Indelicato; Newton Wahome; Philippe Ringler; Shirley A Müller; Mu-Ping Nieh; Peter Burkhard; Reidun Twarock
Journal:  Biophys J       Date:  2016-02-02       Impact factor: 4.033

2.  A self-adjuvanting supramolecular vaccine carrying a folded protein antigen.

Authors:  Gregory A Hudalla; Justin A Modica; Ye F Tian; Jai S Rudra; Anita S Chong; Tao Sun; Milan Mrksich; Joel H Collier
Journal:  Adv Healthc Mater       Date:  2013-02-25       Impact factor: 9.933

Review 3.  Applications and perspectives of nanomaterials in novel vaccine development.

Authors:  Yingbin Shen; Tianyao Hao; Shiyi Ou; Churan Hu; Long Chen
Journal:  Medchemcomm       Date:  2017-10-17       Impact factor: 3.597

Review 4.  Nanoscale assemblies and their biomedical applications.

Authors:  Tais A P F Doll; Senthilkumar Raman; Raja Dey; Peter Burkhard
Journal:  J R Soc Interface       Date:  2013-01-09       Impact factor: 4.118

5.  Malaria vaccine based on self-assembling protein nanoparticles.

Authors:  Peter Burkhard; David E Lanar
Journal:  Expert Rev Vaccines       Date:  2015-10-15       Impact factor: 5.217

Review 6.  α-Helical coiled-coil peptide materials for biomedical applications.

Authors:  Yaoying Wu; Joel H Collier
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-09-06

Review 7.  Tolerogenic Nanoparticles to Treat Islet Autoimmunity.

Authors:  Tobias Neef; Stephen D Miller
Journal:  Curr Diab Rep       Date:  2017-08-08       Impact factor: 4.810

8.  Engaging adaptive immunity with biomaterials.

Authors:  Carolina Mora-Solano; Joel H Collier
Journal:  J Mater Chem B       Date:  2014-05-07       Impact factor: 6.331

Review 9.  Particle-based platforms for malaria vaccines.

Authors:  Yimin Wu; David L Narum; Sylvain Fleury; Gary Jennings; Anjali Yadava
Journal:  Vaccine       Date:  2015-10-11       Impact factor: 3.641

Review 10.  Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications.

Authors:  Christopher D Spicer; Coline Jumeaux; Bakul Gupta; Molly M Stevens
Journal:  Chem Soc Rev       Date:  2018-05-21       Impact factor: 54.564

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.